Assessment of cancer risk with β-interferon treatment for multiple sclerosis

Meningioma after immunomodulation for multiple sclerosis

(2012) Rodrigo Gonçalves Kleinpaul Vieira et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Cancer risk in multiple sclerosis: findings from British Columbia, Canada

(2012) Elaine Kingwell et al.   BRAIN

Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study

(2012) Charity Evans et al.   CLINICAL THERAPEUTICS

Cancer and multiple sclerosis in the era of disease-modifying treatments

(2011) Christine Lebrun et al.   JOURNAL OF NEUROLOGY

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings

(2011) Magnhild Sandberg-Wollheim et al.   Multiple Sclerosis Journal

New perspectives in the natural history of multiple sclerosis

(2010) H. Tremlett et al.   NEUROLOGY

Interferons and multiple sclerosis: is it plausible that β-IFN treatment could influence the risk of cancer among MS patients?

(2009) Elaine Kingwell et al.   Expert Review of Neurotherapeutics

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

Glatiramer Acetate–Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma

(2008) Monica M. Madray et al.   ARCHIVES OF NEUROLOGY

Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review

(2008) Rodabe N. Amaria et al.   Clinical Breast Cancer

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis

(2008) Christine Lebrun et al.   Multiple Sclerosis Journal